Skip to the content
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
Menu
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
  • Contact
Menu
  • Contact

Identification of immunoreactive linear epitopes of Borrelia miyamotoi.

read more
Path 3
  • Scientific Publication
  • January 1, 2020

Tokarz R, et al. (2020) “Identification of immunoreactive linear epitopes of Borrelia miyamotoi.” Ticks Tick Borne Dis. 11(1): 101314. doi: 10.1016/j.ttbdis.2019.101314

Abstract

Borrelia miyamotoi is an emerging tick-borne spirochete transmitted by ixodid ticks. Current serologic assays for B. miyamotoi are impacted by genetic similarities to other Borrelia and limited understanding of optimal antigenic targets. In this study, we employed the TBD-Serochip, a peptide array platform, to identify new linear targets for serologic detection of B. miyamotoi. We examined a wide range of suspected B. miyamotoi antigens and identified 352 IgM and 91 IgG reactive peptides, with the majority mapping to variable membrane proteins. These included peptides within conserved fragments of variable membrane proteins that may have greater potential for differential diagnosis. We also identified reactive regions on FlaB, and demonstrate crossreactivity of B. burgdorferi s.l. C6 with a B. miyamotoi C6-like peptide. The panel of linear peptides identified in this study can be used to enhance serodiagnosis of B. miyamotoi.

PreviousDr. Jigar Patel, CEO of Nimble Therapeutics, speaks at BIO-Europe® 2019 in Hamburg
NextNimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics
PreviousDr. Jigar Patel, CEO of Nimble Therapeutics, speaks at BIO-Europe® 2019 in Hamburg
NextNimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact

603 Science Dr
Madison, WI, USA 53711

LinkedIn
  • Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
    Read More